Introduction
============

Lung cancer (LC) is the most common malignancy worldwide. It was reported that 1.8 million new LC patients were diagnosed in 2012, which accounted for about 13% of total cancer cases.[@b1-cmar-10-2965] Because of aging, air pollution, smoking, and exposure to occupational and/or environmental carcinogens, LC constitutes a burden all over the world. Some risk factors mentioned above might contribute to the development of LC; however, other susceptibility factors could also increase the incidence of LC. Nowadays, genetic variants were supported to influence the risk of LC, especially non-small-cell lung cancer (NSCLC), which was a common subtype of LC.

In humans, insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is a protein which is encoded by *IGF2BP2* gene.[@b2-cmar-10-2965],[@b3-cmar-10-2965] IGF2BP2 regulates insulin-like growth factor 2 (IGF2) translation by binding to the 5′ UTR of IGF2 mRNA.[@b3-cmar-10-2965] Gu et al reported that IGF2BP2 was overexpression in both ovarian cancer and ovarian low malignant potential tumor samples compared to either normal ovary or ovarian adenomas samples.[@b4-cmar-10-2965] A previous study also found that IGF2BP2/IGF-1/IGF-1 receptor signaling pathways might involve in cancer-mediated endothelial recruitment, which was an important feature of metastatic cancer in the tumor microenvironment.[@b5-cmar-10-2965] In addition, Liu et al found that an lncRNA (IGF2BP2-AS1) was associated with better overall survival in lung squamous cell carcinoma.[@b6-cmar-10-2965] In view of these previous studies, we thought that IGF2BP2 might influence the development of LC.

IGF family involves IGF ligands, IGF receptors, and IGF-binding proteins (IGFBPs). IGF-1 is a potent mitogen and regulates mitogenesis and antiapoptosis.[@b7-cmar-10-2965] IGFBP3, a major binding protein of IGF-1, interacts with IGF-1, regulates its biological activity, and may play important roles in antiproliferation and proapoptosis.[@b8-cmar-10-2965] Papadimitrakopoulou et al reported that IGFBP3 downregulation is an early event during head and neck carcinogenesis.[@b9-cmar-10-2965] Adenoviral IGFBP3 and farnesyltransferase inhibitor might decrease Akt expression and promote NSCLC cell apoptosis in vitro and in vivo.[@b10-cmar-10-2965] Results of a previous study highlighted that IGFBP3 could mediate LC progression. In addition, overexpression of IGFBP3 might induce apoptosis of NSCLC cells and promote cisplatin response in vitro.[@b11-cmar-10-2965]

Several case--control studies focused on the association of *IGF2BP2* and *IGFBP3* polymorphisms with risk to cancer. Results of previous studies indicated that *IGF2BP2* rs4402960 G\>T single-nucleotide polymorphism (SNP) was associated with the development of breast cancer.[@b12-cmar-10-2965] Terry et al found that *IGFBP3* rs2270628 variants increased IGF1 levels in plasma and was associated with the risk of ovarian cancer.[@b13-cmar-10-2965] In addition, *IGFBP3* rs3110697 variants were significantly associated with IGFBP-3 levels in a multiethnic populations,[@b14-cmar-10-2965] and *IGFBP3* rs3110697 AA genotypes increased the risk of death among Chinese postmenopausal women with breast cancer.[@b15-cmar-10-2965] However, the relationship between *IGF2BP2* and *IGFBP3* polymorphisms and NSCLC risk was unclear. With an aim to determine the potential association of genetic variations in *IGF2BP2* and *IGFBP3* genes with risk of NSCLC in Eastern Chinese Han populations, *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A SNPs were selected and genotyped in 521 NSCLC patients and 1,030 cancer-free controls.

Materials and methods
=====================

Ethics statement
----------------

This case--control study conformed to the Helsinki declaration and was approved by the Institutional Review Board of Fujian Medical University. A written consent was obtained from each participant.

Subjects
--------

In our study, a total of 521 sporadic NSCLC cases and 1,030 age- and gender-matched controls were enrolled. All participants were recruited from the Department of Thoracic Surgery in Affiliated Union Hospital of Fujian Medical University and Affiliated People's Hospital of Jiangsu University. All NSCLC patients (mean age at 59.76±10.71 years) were diagnosed by pathology. The corresponding information was retrieved from medical files ([Table 1](#t1-cmar-10-2965){ref-type="table"}). The cancer-free controls were well-matched to NSCLC patients by age (mean age at 60.34±9.11 years) and sex (*P*=0.453). Individuals without any history of personal malignancy or autoimmune disorder were included as controls. Both NSCLC cases and controls were hereditarily unrelated and were from Eastern Chinese Han population. Each participant was informed about the study protocols and a written consent was obtained. A body mass index (BMI) ≥24 kg/m^2^ was considered as the criterion of Chinese individuals with obesity and overweight.[@b16-cmar-10-2965],[@b17-cmar-10-2965] The definitions of "ever smokers" and "ever drinkers" were described in our previous study.[@b18-cmar-10-2965]

Selection of SNPs
-----------------

To assess the relationship between *IGF2BP2* and *IGFBP3* SNPs and NSCLC risk, we selected polymorphisms in *IGF2BP2* and *IGFBP3* gene according to the publications, which were associated with the development of cancer.[@b12-cmar-10-2965],[@b13-cmar-10-2965],[@b19-cmar-10-2965]--[@b21-cmar-10-2965]

DNA extraction and genotyping
-----------------------------

Using a universal Promega DNA kit (Promega Corporation, Fitchburg, WI, USA), genomic DNA was extracted from whole blood sample which was stored with EDTA-anticoagulation tube. *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T,[@b22-cmar-10-2965] rs3110697 G\>A and rs6953668 G\>A genotypes were determined by a custom-by-design 48-Plex PCR (SNPscan™ kit; Genesky Biotechnologies Inc., Shanghai, China).[@b23-cmar-10-2965] We used ABI 3730XL sequencer to obtain genotypes. The data were read out by GeneMapper 4.1 software (Thermo Fisher Scientific, Waltham, MA, USA). For quality control, 4% samples were randomly selected from 1,551 DNA samples and analyzed again. The genotypes of *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A and rs6953668 G\>A polymorphisms were not changed.

Statistical analysis
--------------------

Age and BMI are expressed as mean ± SD. Student's *t*-test was used to compare these continuous variables between NSCLC cases and cancer-free controls. The categorical variables (eg, *IGF2BP2* and *IGFBP3* genotypes, BMI, gender, age, tobacco use, and drinking status) were compared by using chi-squared test (χ^2^) or Fisher's exact test. Whether the *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A and rs6953668 G\>A genotypes in controls conformed to Hardy--Weinberg equilibrium (HWE) was determined by an Internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>).[@b24-cmar-10-2965]--[@b30-cmar-10-2965] A *P*\<0.05 (two-tailed) was accepted as the criterion of statistical signifi-cance. The relationship between *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A and rs6953668 G\>A polymorphisms with NSCLC susceptibility was assessed by crude/adjusted ORs and 95% CIs. Adjusted for gender, age, tobacco use, drinking status, and BMI, multivariate linear regression was carried out to evaluate the relationship of these SNPs with susceptibility to NSCLC. We used an online SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>)[@b31-cmar-10-2965] to establish haplotypes of *IGF2BP2* and *IGFBP3* genes. We used SAS 9.4 software (windows version; SAS Institute Inc., Cary, NC, USA) to do all statistical analyses.

Results
=======

Baseline characteristics
------------------------

A total of 521 NSCLC cases were included in this study. The mean age of NSCLC cases was 59.76 years (SD: 10.71 years). Among them, 415 were adenocarcinoma (79.65%), 85 were squamous cell carcinoma (16.31%), and 21 were other subtype of NSCLC (4.03%). NSCLC patients included 315 cases with stage I/II and 206 with stage III/IV. Disease staging was determined according to American Joint Committee on Cancer criteria (version 7, 2010). We recruited 1,030 non-cancer controls, involving 588 males (57.09%) and 442 females (42.91%). Their mean ± SD age was 60.34±9.11 years. Characteristics of NSCLC cases and controls included in this study are listed in [Table 1](#t1-cmar-10-2965){ref-type="table"}. The primary information for *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A SNPs was shown in [Table 2](#t2-cmar-10-2965){ref-type="table"}. The successful ratio was \>99.00% for each SNP. Minor allele frequency (MAF) of *IGF2BP2* and *IGFBP3* SNPs was similar to the data in Chinese database ([Table 2](#t2-cmar-10-2965){ref-type="table"}). In controls, the genotype frequencies for *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms were in HWE ([Table 2](#t2-cmar-10-2965){ref-type="table"}).

Association of *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms with NSCLC
------------------------------------------------------------------------------------------------------------------------------------------------

[Table 3](#t3-cmar-10-2965){ref-type="table"} showed the frequencies of *IGF2BP2* and *IGFBP3* genotypes in different NSCLC subgroups and control group. Results of the single locus analyses were summarized in [Table 4](#t4-cmar-10-2965){ref-type="table"}. We found that there was no difference in *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A genotype distribution among overall NSCLC patients and controls. In addition, similar findings were also identified among different NSCLC subtype and controls.

Association of IGF2BP2 rs1470579 A\>C, rs4402960 G\>T and IGFBP3 rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms with NSCLC in a stratification analysis
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As shown in [Table 5](#t5-cmar-10-2965){ref-type="table"}, the stratified analyses suggested that *IGF2BP2* rs1470579 A\>C polymorphism decreased the risk of NSCLC in some subgroups (female subgroup: CC vs AA: adjusted OR =0.46, 95% CI =0.23--0.94, *P*=0.032 and CC vs AC/AA: adjusted OR =0.46, 95% CI =0.23--0.92, *P*=0.028; \<60 years subgroup: CC vs AA: adjusted OR =0.36, 95% CI =0.16--0.80, *P*=0.012 and CC vs AC/AA: adjusted OR =0.37, 95% CI =0.17--0.81, *P*=0.013; and never drinking subgroup: CC vs AA: adjusted OR =0.61, 95% CI =0.37--0.99, *P*=0.046 and CC vs AC/AA: adjusted OR =0.59, 95% CI =0.36--0.95, *P*=0.031).

As shown in [Table 6](#t6-cmar-10-2965){ref-type="table"}, we also found that *IGF2BP2* rs4402960 G\>T polymorphism decreased the risk of NSCLC in some subgroups (female subgroup: TT vs GG: adjusted OR =0.46, 95% CI =0.21--0.93, *P*=0.031 and TT vs GT/GG: adjusted OR =0.44, 95% CI =0.21--0.91, *P*=0.026; \<60 subgroup: TT vs GG: adjusted OR =0.44, 95% CI =0.20--0.95, *P*=0.037 and TT vs GT/GG: adjusted OR =0.45, 95% CI =0.21--0.96, *P*=0.038; and never drinking subgroup: TT vs GT/GG: adjusted OR =0.61, 95% CI =0.37--0.99, *P*=0.046).

However, we found no significant difference in *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A genotype distribution among NSCLC cases and controls ([Tables 7](#t7-cmar-10-2965){ref-type="table"}[](#t8-cmar-10-2965){ref-type="table"}--[9](#t9-cmar-10-2965){ref-type="table"}, respectively).

SNP haplotypes
--------------

We harnessed an online SHEsis software[@b31-cmar-10-2965] to establish haplo-types of *IGF2BP2* and *IGFBP3* gene ([Table 10](#t10-cmar-10-2965){ref-type="table"}). Finally, 19 haplotypes of *IGF2BP2* and *IGFBP3* genes were constructed. When A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~ haplotype was used as reference, A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~A~rs6953668~ haplotype decreased susceptibility to NSCLC (*P*=0.007, [Table 10](#t10-cmar-10-2965){ref-type="table"}).

Discussion
==========

In this study, we explored the potential relationship of *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A SNPs with susceptibility to NSCLC. We found that *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms might not confer risk to overall NSCLC. However, in stratified analyses, we found significant associations between *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T polymorphisms and decreased risk of NSCLC in female, \<60 years, and never drinking subgroups. We also found that A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~A~rs6953668~ haplotype decreased susceptibility to NSCLC. To our knowledge, the present study was the first investigation to identify the correlation between *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T polymorphisms and the decreased risk of NSCLC in Asians.

Dai et al reported that IGF2BP2 is a tumor promoter which promotes malignancy proliferation through its client mRNAs IGF2 and high mobility group A1.[@b32-cmar-10-2965] In many human malignancies, the gene encoding IGF2BP2 was found to be amplified and overexpressed. Recently, Barghash et al found that elevated expression of IGF2BP2 was associated with a shorter survival and metastasis in esophageal adenocarcinoma.[@b33-cmar-10-2965] Several case--control studies reported that *IGF2BP2* rs4402960 G\>T polymorphism was associated with the risk of T2DM and might affect the therapeutic efficacy of antidiabetic in Chinese population.[@b34-cmar-10-2965],[@b35-cmar-10-2965] We found that the *IGF2BP2* rs4402960 TT genotype was associated with the decreased susceptibility of NSCLC among female, \<60 years, and never drinking patients. Previous report showed that *IGF2BP2* rs4402960 G\>T polymorphism was associated with the increased risk of breast cancer in a Chinese population.[@b12-cmar-10-2965] The other case--control study did not find any association between *IGF2BP2* rs4402960 G\>T polymorphism and colorectal cancer.[@b36-cmar-10-2965] We identified that *IGF2BP2* rs4402960 T allele might probably be a protective factor for NSCLC, which was not consistent with the findings of previous studies. It is believed that there are some LC-related driver genes possessing low frequency variant, which modify the states of chromatin or DNA.[@b37-cmar-10-2965] In addition, intronic region could bind to some proteins and even directly alter special gene transcription.[@b37-cmar-10-2965]--[@b39-cmar-10-2965] rs4402960 G\>T polymorphism is located in the intron region of *IGF2BP2* gene, which may influence the post-transcription process. *IGF2BP2* rs4402960 G\>T polymorphism may accordingly alter the risk of NSCLC through post-transcription process mechanisms, and our study suggested that *IGF2BP2* rs4402960 TT genotype and T allele play an important role in lung carcinogenesis. In the future, the function of the *IGF2BP2* rs4402960 G\>T polymorphism needs to be explored in NSCLC patients. A replicated study should also be carried out.

We found that there was a significant difference in genotype distribution of *IGF2BP2* rs1470579 A\>C polymorphism between NSCLC patients and controls in female, \<60 years, and never drinking subgroups. The *IGF2BP2* rs1470579 CC genotype was less frequent in NSCLC cases compared with controls in some subgroups, suggesting that *IGF2BP2* rs1470579 CC genotype decreased the risk of NSCLC. Recent reports showed that *IGF2BP2* rs1470579 A\>C SNP might play important roles in different diseases. Some previous studies suggested that *IGF2BP2* rs1470579 A\>C was associated with the risk of type 2 diabetes mellitus (T2DM). For example, Horikawa et al found that this SNP was a susceptibility marker for T2DM in a Japanese population,[@b40-cmar-10-2965] and Huang et al found that this SNP was a risk factor for T2DM in a Chinese population.[@b35-cmar-10-2965] In addition, a quantitative assessment demonstrated that this common polymorphism was associated with the development of T2DM. Therefore, whether the A-to-C variant in the intron region of *IGF2BP2* gene does influence the expression of *IGF2BP2* gene needs to be further studied.

Using SHEsis software,[@b31-cmar-10-2965] we constructed 19 haplotypes to assess the potential inherited patterns of *IGF2BP2* and *IGFBP3* genes. Compared with A~rs1470579~C~rs2270628~G~rs3110697~G~rs-4402960~G~rs6953668~ haplotype, we found that A~rs1470579~C~rs2270628~G~rs-3110697~G~rs4402960~A~rs6953668~ haplotype significantly decreased the risk of NSCLC (*P*=0.007, [Table 10](#t10-cmar-10-2965){ref-type="table"}). To the best of our knowledge, we first identified the relationship of this haplotypes with susceptibility to NSCLC. However, this rare haplotype only influenced a very minor fraction (\<1%) of the studied populations. In the future, more studies with a larger sample size and an adequate methodological quality should be performed to confirm or refute these primary findings.

Some limitations in the current study should be acknowledged. First, we selected only some functional polymorphisms in *IGF2BP2* and *IGFBP3* genes. In the future, a fine-mapping study should be conducted to further study the potential relationship of *GF2BP2* and *IGFBP3* polymorphisms with risk of NSCLC. Second, in this case--control study, the sample size of NSCLC patients was relatively limited, which might lead to lack of sufficient power to identify true correlation, especially in the subgroup analysis. In the future, more NSCLC cases and controls should be enrolled, and a replicated study should be carried out. Third, this case--control study was hospital-based. The cancer-free controls recruited from local hospitals might not completely represent a general Eastern Chinese Han population. Fourth, the genotype frequencies of *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms were not in HWE, which might lead to bias. Fifth, a functional experimentation was not performed. Finally, because of the lack of the information on survival of NSCLC, we did not further analyze the role of *GF2BP2* and *IGFBP3* variants on NSCLC prognosis.

Conclusion
==========

Our study suggests that *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T polymorphisms are candidates for decreased susceptibility to NSCLC in Eastern Chinese Han population among female, \<60 years, and never drinking subgroups. Compared with A~rs1470579~ C~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~ haplotype, A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~A~rs6953668~ haplotype significantly decreased risk of NSCLC. In the future, more case--control studies with comprehensive resequencing or SNP functional analysis are needed to confirm these preliminary findings.
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###### 

Distribution of selected demographic variables and risk factors in NSCLC cases and controls

  Variables                  Overall cases (n=521)   Overall controls (n=1,030)   *P*-value[a](#tfn2-cmar-10-2965){ref-type="table-fn"}
  -------------------------- ----------------------- ---------------------------- -------------------------------------------------------
  Age (years)                59.76±10.71             60.34±9.11                   0.268
  Age (years)                                                                     0.843
   \<60                      238 (45.68)             476 (46.21)                  
   ≥60                       283 (54.32)             554 (53.79)                  
  Sex                                                                             0.453
   Male                      287 (55.09)             588 (57.09)                  
   Female                    234 (44.91)             442 (42.91)                  
  Smoking status                                                                  **\<0.001**
   Never                     317 (60.84)             828 (80.39)                  
   Ever                      204 (39.16)             202 (19.61)                  
  Alcohol use                                                                     **\<0.001**
   Never                     444 (85.22)             949 (92.14)                  
   Ever                      77 (14.78)              81 (7.86)                    
   BMI (kg/m^2^)             23.00±3.03              23.84±3.06                   **\<0.001**
  BMI (kg/m^2^)                                                                   
   \<24                      337 (64.68)             547 (53.11)                  **\<0.001**
   ≥24                       184 (35.32)             483 (46.89)                  
  Lymph node status                                                               
   Positive                  200 (38.39)                                          
   Negative                  314 (60.27)                                          
   Unknown                   7 (1.34)                                             
  TNM stage                                                                       
   I+II                      315 (60.46)                                          
   I+IV                      206 (39.54)                                          
  Type of NSCLC                                                                   
   Adenocarcinoma            415 (79.65)                                          
   Squamous cell carcinoma   85 (16.31)                                           
   Others                    21 (4.03)                                            

**Notes:** Bold values are statistically significant (*P*\<0.05).

Two-sided chi-squared test and Student's *t*-test.

**Abbreviations:** BMI, body mass index; NSCLC, non-small-cell lung cancer; TNM, tumor-lymph node-metastasis.

###### 

Primary information for *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms

  Genotyped SNPs             Chromosome   Chr Pos (NCBI Build 38)   MAF for Chinese in database   MAF in our controls (n=1,030)   *P*-value for HWE test in our controls   Genotyping method   Genotyping value (%)
  -------------------------- ------------ ------------------------- ----------------------------- ------------------------------- ---------------------------------------- ------------------- ----------------------
  *IGF2BP2* rs1470579 A\>C   3            185811292                 0.27                          0.25                            0.001                                    SNPscan             99.94
  *IGF2BP2* rs4402960 G\>T   3            185793899                 0.26                          0.25                            0.001                                    SNPscan             99.94
  *IGFBP3* rs2270628 C\>T    7            45909971                  0.21                          0.19                            0.672                                    SNPscan             99.94
  *IGFBP3* rs3110697 G\>A    7            45915430                  0.23                          0.26                            0.102                                    SNPscan             99.94
  *IGFBP3* rs6953668 G\>A    7            45916276                  0.04                          0.05                            0.565                                    SNPscan             99.87

**Abbreviations:** MAF, minor allele frequency; HWE, Hardy--Weinberg equilibrium; SNP, single-nucleotide polymorphism.

###### 

The frequencies of *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A and rs6953668 G\>A polymorphisms in different NSCLC subgroups

  Genotype                   NSCLC cases (n=521)   Adenocarcinoma (n=415)   Non-adenocarcinoma (n=106)   Controls (n=1,030)                      
  -------------------------- --------------------- ------------------------ ---------------------------- -------------------- ---- ------- ----- -------
  *IGF2BP2* rs1470579 A\>C                                                                                                                       
   AA                        302                   58.54                    241                          58.07                61   57.55   593   57.63
   AC                        187                   35.89                    148                          35.66                39   36.79   350   34.01
   CC                        32                    6.14                     26                           6.27                 6    5.66    86    8.36
   C allele                  251                   24.09                    200                          24.10                51   24.06   522   25.36
  *IGF2BP2* rs4402960 G\>T                                                                                                                       
   GG                        306                   58.73                    244                          58.80                62   58.49   603   58.60
   GT                        185                   35.51                    146                          35.18                39   36.79   344   33.43
   TT                        30                    5.76                     25                           6.03                 5    4.72    82    7.97
   T allele                  245                   23.51                    196                          23.61                49   23.11   508   24.68
  *IGFBP3* rs2270628 C\>T                                                                                                                        
   CC                        334                   64.11                    273                          65.78                61   57.55   670   65.11
   CT                        163                   31.29                    122                          29.40                41   38.68   318   30.90
   TT                        24                    4.61                     20                           4.82                 4    3.77    41    3.98
   T allele                  211                   20.25                    162                          19.52                49   23.11   400   19.44
  *IGFBP3* rs3110697 G\>A                                                                                                                        
   GG                        286                   54.89                    235                          56.63                51   48.11   578   56.17
   GA                        190                   36.47                    142                          34.22                48   45.28   373   36.25
   AA                        45                    8.64                     38                           9.16                 7    6.60    78    7.58
   A allele                  280                   26.87                    218                          26.27                62   29.25   529   25.70
  *IGFBP3* rs6953668 G\>A                                                                                                                        
   GG                        466                   89.44                    375                          90.36                91   85.85   920   89.49
   GA                        53                    10.17                    39                           9.40                 14   13.21   104   10.12
   AA                        2                     0.38                     1                            0.24                 1    0.94    4     0.39
   A allele                  57                    5.47                     41                           4.94                 16   7.55    112   5.45

**Abbreviation:** NSCLC, non-small-cell lung cancer.

###### 

Logistic regression analyses of association of *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T and *IGFBP3* rs2270628 C\>T, rs3110697 G\>A, and rs6953668 G\>A polymorphisms with risk of NSCLC

  Genotype                   Overall NSCLC cases (n=521) vs controls (n=1,030)   Adenocarcinoma (n=415) vs controls (n=1,030)   Non-adenocarcinoma (n=106) vs controls (n=1,030)                                                                                                                     
  -------------------------- --------------------------------------------------- ---------------------------------------------- -------------------------------------------------- ------- ------------------- ------- ------------------- ------- -------------------- ------- -------------------- -------
  *IGF2BP2* rs1470579 A\>C                                                                                                                                                                                                                                                                           
   Additive model            1.05 (0.84--1.32)                                   0.666                                          1.03 (0.82--1.30)                                  0.800   1.04 (0.82--1.33)   0.739   1.03 (0.80--1.33)   0.805   1.09 (0.71--1.66)    0.705   1.04 (0.65--1.66)    0.859
   Homozygote model          0.73 (0.48--1.12)                                   0.154                                          0.72 (0.46--1.12)                                  0.143   0.75 (0.47--1.19)   0.214   0.73 (0.46--1.18)   0.200   0.68 (0.29--1.62)    0.383   0.67 (0.26--1.70)    0.393
   Dominant model            0.99 (0.80--1.22)                                   0.899                                          0.97 (0.78--1.21)                                  0.775   0.98 (0.78--1.24)   0.877   0.97 (0.77--1.23)   0.814   1.00 (0.67--1.50)    0.987   0.97 (0.62--1.52)    0.893
   Recessive model           0.72 (0.47--1.09)                                   0.122                                          0.71 (0.46--1.10)                                  0.121   0.73 (0.47--1.15)   0.180   0.73 (0.46--1.15)   0.174   0.66 (0.28--1.54)    0.336   0.65 (0.26--1.64)    0.364
  *IGF2BP2* rs4402960 G\>T                                                                                                                                                                                                                                                                           
   Additive model            1.06 (0.85--1.33)                                   0.604                                          1.03 (0.82--1.30)                                  0.801   1.05 (0.82--1.34)   0.692   1.03 (0.80--1.33)   0.802   1.10 (0.72--1.68)    0.644   1.03 (0.65--1.65)    0.889
   Homozygote model          0.72 (0.47--1.12)                                   0.147                                          0.72 (0.46--1.14)                                  0.162   0.76 (0.47--1.21)   0.243   0.75 (0.47--1.22)   0.251   0.59 (0.23--1.52)    0.278   0.60 (0.22--1.65)    0.324
   Dominant model            1.00 (0.80--1.23)                                   0.960                                          0.97 (0.78--1.21)                                  0.797   0.99 (0.79--1.25)   0.946   0.98 (0.77--1.24)   0.857   1.01 (0.67--1.51)    0.983   0.96 (0.61--1.49)    0.840
   Recessive model           0.71 (0.46--1.09)                                   0.114                                          0.71 (0.46--1.12)                                  0.139   0.74 (0.47--1.18)   0.203   0.75 (0.46--1.20)   0.222   0.57 (0.23--1.44)    0.237   0.59 (0.22--1.60)    0.303
  *IGFBP3* rs2270628 C\>T                                                                                                                                                                                                                                                                            
   Additive model            1.03 (0.82--1.30)                                   0.803                                          1.01 (0.79--1.28)                                  0.945   0.94 (0.73--1.21)   0.647   0.92 (0.71--1.19)   0.504   1.42 (0.93--2.15)    0.101   1.43 (0.90--2.27)    0.127
   Homozygote model          1.18 (0.70--1.98)                                   0.542                                          1.13 (0.66--1.95)                                  0.648   1.20 (0.69--2.08)   0.520   1.19 (0.68--2.09)   0.550   1.07 (0.37--3.10)    0.896   1.11 (0.35--3.52)    0.857
   Dominant model            1.05 (0.84--1.30)                                   0.695                                          1.02 (0.81--1.29)                                  0.852   0.97 (0.76--1.23)   0.809   0.95 (0.74--1.21)   0.658   1.38 (0.92--2.07)    0.123   1.40 (0.89--2.18)    0.145
   Recessive model           1.16 (0.70--1.95)                                   0.564                                          1.13 (0.66--1.93)                                  0.654   1.22 (0.71--2.11)   0.476   1.22 (0.70--2.14)   0.485   0.95 (0.33--2.69)    0.916   0.97 (0.31--3.04)    0.963
  *IGFBP3* rs3110697 G\>A                                                                                                                                                                                                                                                                            
   Additive model            1.03 (0.82--1.29)                                   0.789                                          1.02 (0.80--1.28)                                  0.902   0.94 (0.73--1.20)   0.609   0.93 (0.72--1.19)   0.549   1.46 (0.97--2.21)    0.073   1.53 (0.97--2.43)    0.068
   Homozygote model          1.17 (0.79--1.73)                                   0.439                                          1.18 (0.79--1.79)                                  0.420   1.20 (0.79--1.82)   0.390   1.21 (0.79--1.85)   0.388   1.02 (0.45--2.32)    0.965   0.89 (0.36--2.19)    0.805
   Dominant model            1.05 (0.85--1.30)                                   0.632                                          1.04 (0.84--1.30)                                  0.712   0.98 (0.78--1.24)   0.875   0.97 (0.77--1.23)   0.820   1.38 (0.93--2.06)    0.113   1.41 (0.91--2.19)    0.129
   Recessive model           1.15 (0.79--1.69)                                   0.467                                          1.18 (0.79--1.75)                                  0.426   1.23 (0.82--1.84)   0.319   1.24 (0.82--1.89)   0.306   0.86 (0.39--1.92)    0.716   0.74 (0.31--1.77)    0.501
  *IGFBP3* rs6953668 G\>A                                                                                                                                                                                                                                                                            
   Additive model            1.01 (0.71--1.43)                                   0.963                                          1.05 (0.73--1.51)                                  0.808   0.92 (0.63--1.36)   0.681   0.94 (0.63--1.40)   0.772   1.36 (0.75--2.48)    0.309   1.45 (0.74--2.83)    0.277
   Homozygote model          0.99 (0.18--5.42)                                   0.990                                          0.60 (0.11--3.40)                                  0.562   0.62 (0.07--5.52)   0.664   0.48 (0.05--4.40)   0.519   2.53 (0.28--22.91)   0.408   1.32 (0.13--13.49)   0.816
   Dominant model            1.01 (0.71--1.42)                                   0.980                                          1.02 (0.71--1.46)                                  0.908   0.91 (0.62--1.33)   0.623   0.92 (0.62--1.36)   0.679   1.40 (0.79--2.51)    0.253   1.44 (0.75--2.76)    0.272
   Recessive model           0.99 (0.18--5.40)                                   0.988                                          0.60 (0.11--3.38)                                  0.559   0.62 (0.07--5.55)   0.668   0.49 (0.05--4.42)   0.522   2.44 (0.27--22.02)   0.427   1.26 (0.12--12.93)   0.844

**Note:**

Adjusted for age, sex, smoking status, alcohol use, and BMI status.

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

Stratified analyses between *IGF2BP2* rs1470579 A\>C polymorphism and NSCLC risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *IGF2BP2* rs1470579 A\>C (case/control)[a](#tfn8-cmar-10-2965){ref-type="table-fn"}   Adjusted OR[b](#tfn9-cmar-10-2965){ref-type="table-fn"} (95% CI); *P*                                                                                                       
  --------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------- ------ -------------------------- ------------------------------ -------------------------- ------------------------------
  Sex                                                                                                                                                                                                                                                                                     
   Male                 165/344                                                                               101/198                                                                 21/45   1.00   1.05 (0.76--1.45); 0.789   1.00 (0.55--1.81); 0.999       1.04 (0.76--1.41); 0.824   0.98 (0.55--1.76); 0.953
   Female               137/249                                                                               86/152                                                                  11/41   1.00   1.01 (0.72--1.43); 0.935   **0.46 (0.23--0.94); 0.032**   0.90 (0.65--1.24); 0.506   **0.46 (0.23--0.92); 0.028**
  Age                                                                                                                                                                                                                                                                                     
   \<60                 148/273                                                                               82/159                                                                  8/43    1.00   0.94 (0.66--1.33); 0.725   **0.36 (0.16--0.80); 0.012**   0.82 (0.59--1.14); 0.237   **0.37 (0.17--0.81); 0.013**
   ≥60                  154/320                                                                               105/191                                                                 24/43   1.00   1.12 (0.82--1.54); 0.479   1.08 (0.62--1.89); 0.787       1.11 (0.83--1.51); 0.481   1.03 (0.60--1.78); 0.909
  Smoking status                                                                                                                                                                                                                                                                          
   Never                185/471                                                                               113/284                                                                 19/72   1.00   1.00 (0.76--1.33); 0.978   0.64 (0.37--1.11); 0.111       0.93 (0.71--1.21); 0.585   0.64 (0.38--1.09); 0.102
   Ever                 117/122                                                                               74/66                                                                   13/14   1.00   1.12 (0.73--1.70); 0.610   0.89 (0.40--1.99); 0.771       1.08 (0.72--1.61); 0.720   0.85 (0.39--1.87); 0.688
  Alcohol consumption                                                                                                                                                                                                                                                                     
   Never                259/548                                                                               161/318                                                                 24/82   1.00   1.09 (0.85--1.40); 0.510   **0.61 (0.37--0.99); 0.046**   0.99 (0.78--1.25); 0.908   **0.59 (0.36--0.95); 0.031**
   Ever                 43/45                                                                                 26/32                                                                   8/4     1.00   0.76 (0.38--1.51); 0.427   2.23 (0.58--8.50); 0.242       0.90 (0.47--1.72); 0.740   2.51 (0.68--9.25); 0.168
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                           
   \<24                 189/303                                                                               125/191                                                                 23/52   1.00   1.03 (0.76--1.39); 0.842   0.69 (0.40--1.19); 0.183       0.96 (0.72--1.27); 0.760   0.68 (0.40--1.16); 0.158
   ≥24                  113/290                                                                               62/159                                                                  9/34    1.00   1.04 (0.72--1.52); 0.823   0.78 (0.35--1.70); 0.526       1.00 (0.70--1.43); 0.996   0.76 (0.35--1.65); 0.494

**Notes:**

For *IGF2BP2* rs1470579 A\>C, the genotyping was successful in 521 (100.00%) NSCLC cases and 1,029 (99.90%) controls.

Adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model. Bold values are statistically significant (*P*\<0.05).

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

Stratified analyses between *IGF2BP2* rs4402960 G\>T polymorphism and NSCLC risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *IGF2BP2* rs4402960 G\>T (case/control)[a](#tfn11-cmar-10-2965){ref-type="table-fn"}   Adjusted OR[b](#tfn12-cmar-10-2965){ref-type="table-fn"} (95% CI); *P*                                                                                                       
  --------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------- ------ -------------------------- ------------------------------ -------------------------- ------------------------------
  Sex                                                                                                                                                                                                                                                                                       
   Male                 168/349                                                                                99/195                                                                   20/43   1.00   1.02 (0.74--1.41); 0.905   1.04 (0.57--1.90); 0.902       1.02 (0.75--1.39); 0.893   1.03 (0.57--1.86); 0.922
   Female               138/254                                                                                86/149                                                                   10/39   1.00   1.03 (0.73--1.46); 0.852   **0.46 (0.21--0.93); 0.031**   0.91 (0.66--1.26); 0.574   **0.44 (0.21--0.91); 0.026**
  Age (years)                                                                                                                                                                                                                                                                               
   \<60                 147/277                                                                                82/158                                                                   9/40    1.00   0.96 (0.68--1.36); 0.817   **0.44 (0.20--0.95); 0.037**   0.86 (0.61--1.20); 0.361   **0.45 (0.21--0.96); 0.038**
   ≥60                  159/326                                                                                103/186                                                                  21/42   1.00   1.10 (0.80--1.52); 0.555   0.99 (0.56--1.77); 0.975       1.08 (0.80--1.46); 0.615   0.96 (0.54--1.68); 0.875
  Smoking status                                                                                                                                                                                                                                                                            
   Never                188/480                                                                                111/278                                                                  18/69   1.00   1.00 (0.76--1.33); 0.979   0.64 (0.37--1.12); 0.117       0.93 (0.71--1.22); 0.593   0.64 (0.37--1.10); 0.109
   Ever                 118/123                                                                                74/66                                                                    12/13   1.00   1.12 (0.73--1.70); 0.608   0.91 (0.40--2.09); 0.823       1.08 (0.73--1.62); 0.698   0.87 (0.39--1.98); 0.744
  Alcohol consumption                                                                                                                                                                                                                                                                       
   Never                263/555                                                                                157/314                                                                  24/79   1.00   1.06 (0.83--1.36); 0.647   0.62 (0.38--1.02); 0.061       0.97 (0.76--1.23); 0.801   **0.61 (0.37--0.99); 0.046**
   Ever                 43/48                                                                                  28/30                                                                    6/3     1.00   0.92 (0.46--1.82); 0.802   2.73 (0.58--12.72); 0.202      1.05 (0.54--2.02); 0.895   2.83 (0.62--12.84); 0.179
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                             
   \<24                 194/306                                                                                121/192                                                                  22/48   1.00   0.96 (0.71--1.30); 0.780   0.71 (0.41--1.24); 0.232       0.91 (0.68--1.21); 0.507   0.72 (0.42--1.25); 0.244
   ≥24                  112/297                                                                                64/152                                                                   8/34    1.00   1.17 (0.80--1.71); 0.413   0.73 (0.32--1.64); 0.442       1.09 (0.76--1.57); 0.628   0.69 (0.31--1.54); 0.361

**Notes:**

For *IGF2BP2* rs4402960 G\>T, the genotyping was successful in 521 (100.00%) NSCLC cases and 1,029 (99.90%) controls.

Adjusted for multiple comparisons (age, sex, BMI, smoking status and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model. Bold values are statistically significant (*P*\<0.05).

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

Stratified analyses between *IGFBP3* rs2270628 C\>T polymorphism and NSCLC risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *IGFBP3* rs2270628 C\>T (case/control)[a](#tfn14-cmar-10-2965){ref-type="table-fn"}   Adjusted OR[b](#tfn15-cmar-10-2965){ref-type="table-fn"} (95% CI); *P*                                                                                                   
  --------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------- ------ -------------------------- -------------------------- -------------------------- --------------------------
  Sex                                                                                                                                                                                                                                                                                  
   Male                 188/382                                                                               84/183                                                                   15/22   1.00   0.91 (0.65--1.27); 0.573   1.39 (0.67--2.88); 0.376   0.96 (0.70--1.32); 0.794   1.43 (0.70--2.94); 0.332
   Female               146/288                                                                               79/135                                                                   9/19    1.00   1.11 (0.79--1.57); 0.554   0.96 (0.42--2.20); 0.920   1.09 (0.78--1.53); 0.605   0.93 (0.41--2.10); 0.854
  Age (years)                                                                                                                                                                                                                                                                          
   \<60                 155/309                                                                               71/152                                                                   12/14   1.00   0.94 (0.66--1.34); 0.735   1.90 (0.81--4.47); 0.139   1.01 (0.72--1.43); 0.940   1.94 (0.83--4.51); 0.125
   ≥60                  179/361                                                                               92/166                                                                   12/27   1.00   1.06 (0.77--1.47); 0.725   0.87 (0.42--1.79); 0.695   1.03 (0.76--1.41); 0.841   0.85 (0.41--1.74); 0.654
  Smoking status                                                                                                                                                                                                                                                                       
   Never                201/541                                                                               103/252                                                                  13/34   1.00   1.07 (0.80--1.42); 0.656   0.98 (0.50--1.92); 0.946   1.06 (0.80--1.39); 0.704   0.96 (0.49--1.86); 0.893
   Ever                 133/129                                                                               60/66                                                                    11/7    1.00   0.88 (0.57--1.35); 0.561   1.53 (0.57--4.08); 0.399   0.94 (0.63--1.42); 0.783   1.59 (0.60--4.21); 0.352
  Alcohol consumption                                                                                                                                                                                                                                                                  
   Never                283/623                                                                               139/287                                                                  22/38   1.00   1.07 (0.83--1.38); 0.594   1.18 (0.67--2.08); 0.560   1.08 (0.85--1.38); 0.515   1.16 (0.66--2.02); 0.611
   Ever                 51/47                                                                                 24/31                                                                    2/3     1.00   0.68 (0.34--1.35); 0.268   0.78 (0.12--5.26); 0.802   0.69 (0.35--1.34); 0.269   0.90 (0.14--5.91); 0.909
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                        
   \<24                 210/353                                                                               107/171                                                                  20/22   1.00   1.08 (0.79--1.47); 0.642   1.58 (0.82--3.05); 0.171   1.13 (0.84--1.52); 0.407   1.54 (0.81--2.95); 0.190
   ≥24                  124/317                                                                               56/147                                                                   4/19    1.00   0.92 (0.63--1.35); 0.670   0.54 (0.18--1.66); 0.285   0.88 (0.60--1.28); 0.493   0.56 (0.18--1.69); 0.303

**Notes:**

For *IGFBP3* rs2270628 C\>T, the genotyping was successful in 521 (100%) NSCLC cases and 1,029 (99.90%) controls.

Adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

Stratified analyses between *IGFBP3* rs3110697 G\>A polymorphism and NSCLC risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *IGFBP3* rs3110697 G\>A (case/control)[a](#tfn17-cmar-10-2965){ref-type="table-fn"}   Adjusted OR[b](#tfn18-cmar-10-2965){ref-type="table-fn"} (95% CI); *P*                                                                                                   
  --------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------- ------ -------------------------- -------------------------- -------------------------- --------------------------
  Sex                                                                                                                                                                                                                                                                                  
   Male                 155/332                                                                               109/208                                                                  23/47   1.00   1.10 (0.80--1.52); 0.571   1.00 (0.56--1.76); 0.986   1.08 (0.79--1.46); 0.634   0.96 (0.55--1.67); 0.879
   Female               131/246                                                                               81/165                                                                   22/31   1.00   0.92 (0.65--1.30); 0.640   1.45 (0.80--2.63); 0.224   1.00 (0.72--1.39); 0.994   1.50 (0.84--2.67); 0.175
  Age (years)                                                                                                                                                                                                                                                                          
   \<60                 129/274                                                                               89/163                                                                   20/38   1.00   1.14 (0.81--1.62); 0.450   1.18 (0.64--2.18); 0.591   1.15 (0.83--1.60); 0.408   1.12 (0.62--2.03); 0.709
   ≥60                  157/304                                                                               101/210                                                                  25/40   1.00   0.93 (0.67--1.28); 0.642   1.18 (0.67--2.06); 0.566   0.97 (0.72--1.31); 0.831   1.21 (0.70--2.09); 0.485
  Smoking status                                                                                                                                                                                                                                                                       
   Never                175/472                                                                               112/295                                                                  30/60   1.00   1.03 (0.78--1.37); 0.835   1.43 (0.88--2.32); 0.146   1.10 (0.84--1.43); 0.506   1.41 (0.88--2.26); 0.149
   Ever                 111/106                                                                               78/78                                                                    15/18   1.00   0.98 (0.65--1.48); 0.920   0.79 (0.38--1.65); 0.527   0.94 (0.64--1.40); 0.767   0.79 (0.39--1.63); 0.531
  Alcohol consumption                                                                                                                                                                                                                                                                  
   Never                243/538                                                                               163/339                                                                  38/71   1.00   1.07 (0.83--1.37); 0.621   1.26 (0.82--1.96); 0.295   1.10 (0.87--1.39); 0.441   1.23 (0.80--1.89); 0.339
   Ever                 43/40                                                                                 27/34                                                                    7/7     1.00   0.69 (0.34--1.38); 0.294   0.80 (0.25--2.54); 0.709   0.71 (0.37--1.37); 0.306   0.94 (0.31--2.86); 0.913
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                        
   \<24                 194/321                                                                               118/184                                                                  25/41   1.00   1.00 (0.74--1.35); 0.999   0.71 (0.57--1.74); 0.995   1.00 (0.75--1.33); 0.993   1.00 (0.58--1.72); 0.998
   ≥24                  92/257                                                                                72/189                                                                   20/37   1.00   1.01 (0.70--1.47); 0.960   1.47 (0.80--2.72); 0.217   1.09 (0.76--1.54); 0.647   1.47 (0.81--2.65); 0.206

**Notes:**

For *IGFBP3* rs3110697 G\>A, the genotyping was successful in 521 (100%) NSCLC cases and 1,029 (99.90%) controls.

Adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

Stratified analyses between *IGFBP3* rs6953668 G\>A polymorphism and NSCLC risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *IGFBP3* rs6953668 G\>A (case/control)[a](#tfn20-cmar-10-2965){ref-type="table-fn"}   Adjusted OR[b](#tfn21-cmar-10-2965){ref-type="table-fn"} (95% CI); *P*                                                                                                  
  --------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ----- ------ -------------------------- --------------------------- -------------------------- ---------------------------
  Sex                                                                                                                                                                                                                                                                                 
   Male                 254/523                                                                               31/60                                                                    2/3   1.00   1.14 (0.70--1.87); 0.593   0.63 (0.10--3.91); 0.623    1.10 (0.68--1.78); 0.700   0.63 (0.10--3.86); 0.613
   Female               212/397                                                                               22/44                                                                    0/1   1.00   0.94 (0.54--1.61); 0.811   --                          0.92 (0.53--1.58); 0.754   --
  Age (years)                                                                                                                                                                                                                                                                         
   \<60                 217/429                                                                               21/43                                                                    0/2   1.00   1.02 (0.57--1.80); 0.960   --                          0.96 (0.54--1.69); 0.877   --
   ≥60                  249/491                                                                               32/61                                                                    2/2   1.00   1.07 (0.66--1.71); 0.791   0.97 (0.13--7.16); 0.974    1.06 (0.67--1.69); 0.802   0.96 (0.13--7.11); 0.969
  Smoking status                                                                                                                                                                                                                                                                      
   Never                281/741                                                                               36/84                                                                    0/1   1.00   1.17 (0.76--1.79); 0.474   --                          1.15 (0.75--1.76); 0.519   --
   Ever                 185/179                                                                               17/20                                                                    2/3   1.00   0.81 (0.41--1.60); 0.534   0.66 (0.11--4.07); 0.655    0.79 (0.41--1.50); 0.468   0.68 (0.11--4.16); 0.672
  Alcohol consumption                                                                                                                                                                                                                                                                 
   Never                399/848                                                                               44/96                                                                    1/3   1.00   1.03 (0.69--1.52); 0.897   0.47 (0.05--4.64); 0.514    1.00 (0.68--1.47); 0.998   0.46 (0.05--4.63); 0.513
   Ever                 67/72                                                                                 9/8                                                                      1/1   1.00   1.16 (0.41--3.26); 0.778   0.82 (0.05--13.69); 0.888   1.12 (0.42--3.00); 0.823   0.80 (0.05--13.34); 0.876
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                       
   \<24                 301/486                                                                               34/60                                                                    2/0   1.00   0.96 (0.61--1.52); 0.862   --                          1.00 (0.64--1.58); 0.991   --
   ≥24                  165/434                                                                               19/44                                                                    0/4   1.00   1.18 (0.65--2.13); 0.584   --                          1.03 (0.57--1.84); 0.930   --

**Notes:**

For *IGFBP3* rs6953668 G\>A, the genotyping was successful in 521 (100%) NSCLC cases and 1,028 (99.81%) controls.

Adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

**Abbreviations:** NSCLC, non-small-cell lung cancer; BMI, body mass index.

###### 

*IGF2BP2* and *IGFBP3* haplotype frequencies (%) in patients and controls and risk of NSCLC

  Haplotypes                                                     Cases (n=1042)   Controls (n=2,060)   Crude OR (95% CI)   *P*-value                        
  -------------------------------------------------------------- ---------------- -------------------- ------------------- ----------- -------------------- -----------
  A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~   444              42.65                888                 43.21       Reference            --
  A~rs1470579~C~rs2270628~A~rs3110697~G~rs4402960~G~rs6953668~   150              14.41                282                 13.72       1.06 (0.85--1.34)    0.596
  C~rs1470579~C~rs2270628~G~rs3110697~T~rs4402960~G~rs6953668~   133              12.78                304                 14.79       0.88 (0.69--1.11)    0.262
  A~rs1470579~T~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~   137              13.16                225                 12.41       1.22 (0.96--1.55)    0.109
  C~rs1470579~C~rs2270628~A~rs3110697~T~rs4402960~G~rs6953668~   47               4.51                 83                  4.04        1.13 (0.78--1.65)    0.516
  C~rs1470579~T~rs2270628~G~rs3110697~T~rs4402960~G~rs6953668~   43               4.13                 74                  3.60        1.16 (0.78--1.72)    0.453
  A~rs1470579~C~rs2270628~A~rs3110697~G~rs4402960~A~rs6953668~   34               3.27                 56                  2.73        1.21 (0.78--1.89)    0.388
  A~rs1470579~T~rs2270628~A~rs3110697~G~rs4402960~G~rs6953668~   16               1.54                 50                  2.43        0.64 (0.36--1.14)    0.125
  C~rs1470579~C~rs2270628~A~rs3110697~T~rs4402960~A~rs6953668~   12               1.15                 15                  0.73        1.60 (0.74--3.45)    0.226
  A~rs1470579~T~rs2270628~A~rs3110697~G~rs4402960~A~rs6953668~   6                0.58                 12                  0.58        1.00 (0.37--2.68)    1.000
  C~rs1470579~T~rs2270628~A~rs3110697~T~rs4402960~G~rs6953668~   4                0.38                 11                  0.54        0.73 (0.23--2.30)    0.785
  C~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~   5                0.48                 7                   0.34        1.43 (0.45--4.53)    0.549
  C~rs1470579~T~rs2270628~A~rs3110697~T~rs4402960~A~rs6953668~   3                0.29                 9                   0.44        0.67 (0.18--2.48)    0.761
  C~rs1470579~C~rs2270628~A~rs3110697~G~rs4402960~G~rs6953668~   2                0.19                 3                   0.15        1.33 (0.22--8.01)    1.000
  A~rs1470579~C~rs2270628~A~rs3110697~T~rs4402960~G~rs6953668~   3                0.29                 2                   0.10        3.00 (0.50--18.03)   0.341
  A~rs1470579~C~rs2270628~G~rs3110697~G~rs4402960~A~rs6953668~   0                0.00                 13                  0.63        --                   **0.007**
  C~rs1470579~T~rs2270628~G~rs3110697~G~rs4402960~G~rs6953668~   0                0.00                 8                   0.39        --                   0.058
  A~rs1470579~T~rs2270628~G~rs3110697~G~rs4402960~A~rs6953668~   0                0.00                 3                   0.15        --                   0.555
  C~rs1470579~T~rs2270628~G~rs3110697~T~rs4402960~A~rs6953668~   0                0.00                 3                   0.15        --                   0.555
  Others                                                         2                0.19                 7                   0.34        0.57 (0.12--2.76)    0.726

**Note:** Bold values are statistically significant (*P*\<0.05).

**Abbreviation:** NSCLC, non-small-cell lung cancer.

[^1]: These authors contributed equally to this work
